Skip to main content

Progressive Multiple Sclerosis

Neurology
5
Pipeline Programs
6
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
2100%
+ 4 programs with unclassified modality

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
human umbilical cord mesenchymal stem cellsPhase 1/21 trial
Active Trials
NCT01364246Unknown20Est. Dec 2014
Beike Bio-Technology
Beike Bio-TechnologyChina - Shenzhen
1 program
1
human umbilical cord mesenchymal stem cellsPhase 1/2
Sandoz
SandozAustria - Kundl
1 program
1
rapcabtagene autoleucelPhase 1/2Cell Therapy1 trial
Active Trials
NCT06675864Recruiting28Est. Jun 2030
Kyverna Therapeutics
Kyverna TherapeuticsCA - Emeryville
1 program
1
KYV-101Phase 11 trial
Active Trials
NCT06451159Active Not Recruiting10Est. Feb 2027
Autolus Therapeutics
1 program
1
Obecabtagene autoleucelPhase 1Cell Therapy1 trial
Active Trials
NCT07139743Recruiting18Est. Aug 2029
Verona Pharma
Verona PharmaUK - London
1 program
Digital TelerehabilitationN/A1 trial
Active Trials
NCT06485115Not Yet Recruiting78Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Sandozrapcabtagene autoleucel
Biocorphuman umbilical cord mesenchymal stem cells
Autolus TherapeuticsObecabtagene autoleucel
Kyverna TherapeuticsKYV-101
Verona PharmaDigital Telerehabilitation

Clinical Trials (5)

Total enrollment: 154 patients across 5 trials

NCT06675864Sandozrapcabtagene autoleucel

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Start: Dec 2024Est. completion: Jun 203028 patients
Phase 1/2Recruiting
NCT01364246Biocorphuman umbilical cord mesenchymal stem cells

Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica

Start: Jan 2010Est. completion: Dec 201420 patients
Phase 1/2Unknown
NCT07139743Autolus TherapeuticsObecabtagene autoleucel

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Start: Aug 2025Est. completion: Aug 202918 patients
Phase 1Recruiting

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Start: Jun 2024Est. completion: Feb 202710 patients
Phase 1Active Not Recruiting
NCT06485115Verona PharmaDigital Telerehabilitation

Telerehabilitation in Progressive Multiple Sclerosis

Start: Jun 2024Est. completion: Jun 202678 patients
N/ANot Yet Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 154 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.